BioScrip (BIOS) Misses Q2 EPS by 14c, Revs Modestly Lower; Reiterates Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- US stocks set for lower open as Iran stalemate lifts oil, yields
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- Goldman Sachs to acquire real estate company LCN for up to $410M
BioScrip Reports Second Quarter 2017 Financial Results
August 8, 2017 8:01 AM EDTNet revenue of $218.1 million, including core product mix of 73.1% compared to 60.3% in the prior year Net loss from continuing operations of $28.7 million, compared to $8.3 million in the prior year, reflecting increased non-cash expenses and interest Adjusted EBITDA of $10.0 million, nearly doubling from the first quarter of 2017 Operating Cash Flow of $6.5 million, reflecting $23 million of operational and working capital improvements over the prior year Liquidity of $50.5 million, including $40.5 million of cash, compared to $16.0 million at March 31, 2017 Restructuring expenses of $3.9 million, primarily costs related to the ongoing optimization of the Companys workforce The Company reaffirms EBITDA guidance and updates revenue guidance
... More